Foundry RD Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1MBLY | MOBILEYE GLOBAL INC | Consumer Cyclical | $7.76B | 10.69% |
2RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 3.97% |
3LCID | LUCID GROUP INC | Consumer Cyclical | $2.87B | 3.95% |
4BHVN | BIOHAVEN LTD | Healthcare | $2.32B | 3.20% |
5VRDN | VIRIDIAN THERAPEUTICS INC | Healthcare | $1.86B | 2.56% |
6SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.82B | 2.50% |
7IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.78B | 2.45% |
8ASAN | ASANA INC | Technology | $1.77B | 2.44% |
9TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 2.34% |
10VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 2.19% |
11NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 2.19% |
12MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.45B | 1.99% |
13YELP | YELP INC | Communication Services | $1.44B | 1.98% |
14FMC | FMC CORP | Basic Materials | $1.40B | 1.93% |
15WLTH | WEALTHFRONT CORP | Technology | $1.38B | 1.90% |
16AI | C3AI INC | Technology | $1.37B | 1.89% |
17NVAX | NOVAVAX INC | Healthcare | $1.35B | 1.86% |
18XNCR | XENCOR INC | Healthcare | $1.30B | 1.78% |
19TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.17B | 1.61% |
20CRTO | CRITEO SA | Communication Services | $1.13B | 1.55% |
21WVE | WAVE LIFE SCIENCES LTD | Healthcare | $1.12B | 1.54% |
22UPWK | UPWORK INC | Industrials | $1.12B | 1.54% |
23EYPT | EYEPOINT INC | Healthcare | $1.12B | 1.54% |
24CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $1.09B | 1.50% |
25OLMA | OLEMA PHARMACEUTICALS INC | Healthcare | $1.00B | 1.38% |
26VOR | VOR BIOPHARMA INC | Healthcare | $980M | 1.35% |
27KURA | KURA ONCOLOGY INC | Healthcare | $964M | 1.33% |
28ANNX | ANNEXON INC | Healthcare | $950M | 1.31% |
29ADTN | ADTRAN HOLDINGS INC | Technology | $944M | 1.30% |
30REPL | REPLIMUNE GROUP INC | Healthcare | $859M | 1.18% |
31SLDB | SOLID BIOSCIENCES INC | Healthcare | $859M | 1.18% |
32TDUP | THREDUP INC | Consumer Cyclical | $852M | 1.17% |
33RPD | RAPID7 INC | Technology | $815M | 1.12% |
34PD | PAGERDUTY INC | Technology | $794M | 1.09% |
35BBOT | BRIDGEBIO ONCOLOGY THERAPEUTICS INC | Healthcare | $686M | 0.94% |
36CARS | CARSCOM INC | Consumer Cyclical | $670M | 0.92% |
37PHR | PHREESIA INC | Healthcare | $662M | 0.91% |
38MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.80% |
39FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $575M | 0.79% |
40YEXT | YEXT INC | Technology | $535M | 0.74% |
41VSTM | VERASTEM INC | Healthcare | $530M | 0.73% |
42SPT | SPROUT SOCIAL INC | Technology | $518M | 0.71% |
43ARVN | ARVINAS INC | Healthcare | $517M | 0.71% |
44DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $517M | 0.71% |
45RGNX | REGENXBIO INC | Healthcare | $511M | 0.70% |
46PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.62% |
47KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $453M | 0.62% |
48VREX | VAREX IMAGING CORP | Healthcare | $444M | 0.61% |
49PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.60% |
50ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $426M | 0.59% |
51CBIO | CRESCENT BIOPHARMA INC | Healthcare | $407M | 0.56% |
52ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $400M | 0.55% |
53STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.54% |
54CRNC | CERENCE INC | Technology | $390M | 0.54% |
55UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.53% |
56BBBY | BED BATH & BEYOND INC | Consumer Cyclical | $372M | 0.51% |
57ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.50% |
58XPER | XPERI INC | Technology | $352M | 0.49% |
59VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.45% |
60LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.43% |
61FHTX | FOGHORN THERAPEUTICS INC | Healthcare | $305M | 0.42% |
62SSTK | SHUTTERSTOCK INC | Communication Services | $272M | 0.37% |
63TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.37% |
64ANGI | ANGI INC | Communication Services | $248M | 0.34% |
65RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $243M | 0.33% |
66ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.33% |
67RXST | RXSIGHT INC | Healthcare | $230M | 0.32% |
68UP | WHEELS UP EXPERIENCE INC | Industrials | $229M | 0.32% |
69SPOK | SPOK HOLDINGS INC | Healthcare | $222M | 0.31% |
70KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.30% |
71SENS | SENSEONICS HOLDINGS INC | Healthcare | $214M | 0.29% |
72KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.29% |
73AGEN | AGENUS INC | Healthcare | $209M | 0.29% |
74IMUX | IMMUNIC INC | Healthcare | $207M | 0.28% |
75DTIL | PRECISION BIOSCIENCES INC | Healthcare | $203M | 0.28% |
76AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.27% |
77TNXP | TONIX PHARMACEUTICALS HOLDING CORP | Healthcare | $198M | 0.27% |
78SRI | STONERIDGE INC | Consumer Cyclical | $197M | 0.27% |
79EGAN | EGAIN CORP | Technology | $180M | 0.25% |
80KRRO | KORRO BIO INC | Healthcare | $177M | 0.24% |
81ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.24% |
82CRBP | CORBUS PHARMACEUTICALS HOLDINGS INC | Healthcare | $167M | 0.23% |
83EXOD | EXODUS MOVEMENT INC | Technology | $152M | 0.21% |
84CHPT | CHARGEPOINT HOLDINGS INC | Consumer Cyclical | $146M | 0.20% |
85PMN | PROMIS NEUROSCIENCES INC | Healthcare | $136M | 0.19% |
86FIRY | FIRY INC | Technology | $130M | 0.18% |
87VTVT | VTV THERAPEUTICS INC | Healthcare | $130M | 0.18% |
88AARD | AARDVARK THERAPEUTICS INC | Healthcare | $128M | 0.18% |
89CUE | CUE BIOPHARMA INC | Healthcare | $126M | 0.17% |
90INSG | INSEEGO CORP | Technology | $122M | 0.17% |
91TCX | TUCOWS INC | Technology | $114M | 0.16% |
92SCOR | COMSCORE INC | Communication Services | $113M | 0.16% |
93GEOS | GEOSPACE TECHNOLOGIES CORP | Energy | $88M | 0.12% |
94RLYB | RALLYBIO CORP | Healthcare | $87M | 0.12% |
95ACET | ADICET BIO INC | Healthcare | $76M | 0.10% |
96CLNN | CLENE INC | Healthcare | $76M | 0.10% |
97BODI | BEACHBODY COMPANY INC | Communication Services | $75M | 0.10% |
98SCLX | SCILEX HOLDING CO | Healthcare | $72M | 0.10% |
99LONA | LEONABIO INC | Healthcare | $68M | 0.09% |
100IMA | IMAGENEBIO INC | Healthcare | $61M | 0.08% |
101SKIL | SKILLSOFT CORP | Consumer Defensive | $58M | 0.08% |
102LNZA | LANZATECH GLOBAL INC | Industrials | $56M | 0.08% |
103STEM | STEM INC | Technology | $56M | 0.08% |
104XLO | XILIO THERAPEUTICS INC | Healthcare | $53M | 0.07% |
105MCRB | SERES THERAPEUTICS INC | Healthcare | $52M | 0.07% |
106TIL | INSTIL BIO INC | Healthcare | $50M | 0.07% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $72.64B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 41% toward Large, 47% toward Growth. +20% unclassified (20 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 106 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Required<= 25.0%Actual49.7%Margin-24.7%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActual12.3 daysMargin-5.3 days
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 106 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 129.5% | 112.2% |
| 3 yearsp.a. | 40.1% | 12.0% |
| 5 yearsp.a. | 25.6% | 4.4% |
| 10 yearsp.a. | 29.2% | 13.9% |
| Since inceptionp.a. | 17.5% | 9.5% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 44.7% | 43.3% |
| 2025 | 59.7% | 27.2% |
| 2024 | 7.9% | -32.9% |
| 2023 | 64.9% | 44.5% |
| 2022 | -25.8% | -15.1% |
| 2021 | 20.3% | -5.3% |
| 2020 | 35.2% | 2.1% |
| 2019 | 58.0% | 45.3% |
| 2018 | -7.9% | 7.9% |
| 2017 | 52.2% | 41.5% |
| 2016 | 41.1% | 21.2% |
| 2015 | -6.7% | 13.1% |
| 2014 | 29.8% | 39.5% |
| 2013 | 47.1% | 28.5% |
| 2012 | 7.7% | -4.1% |
| 2011 | -1.5% | -10.2% |
| 2010 | 28.2% | 1.3% |
| 2009 | 85.4% | 67.4% |
| 2008 | -58.9% | -38.9% |
| 2007 | -18.9% | -40.0% |
| 2006 | 30.7% | 7.0% |
| 2005 | 5.5% | -2.5% |
| 2004 | 10.2% | -11.0% |
| 2003 | 116.1% | 61.6% |
| 2002 | -50.1% | -39.2% |
| 2001 | 18.8% | 75.3% |
| 2000 | 7.8% | 84.3% |
| 1999 | 77.1% | -2.3% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry RD Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks (price > $5, market-cap floor) each month by a RD signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.